Avicenna Pharmaceuticals is utilizing the proprietary NOSH technology platform to develop Enhanced Non-Steroidal Anti-inflammatory Drugs. eNSAIDs are anticipated to have a broader range of activity compared to conventional NSAIDs, while having a significantly improved safety profile.
AVICENNA
Technology
eNSAIDs are designed to release two key short lived biologically active gases, nitric oxide and hydrogen sulfide. These gases compensate for NSAID induced low prostaglandin levels and increase mucosal blood flow and mucosal repair.
Learn more
Applications
Due to their activity and potential safety, eNSAIDs are promising anti-cancer agents. However, eNSAIDs would be useful for indications where chronic dosing with NSAIDs is desirable, but currently not feasible such as in the treatment of chronic inflammatory pain, prevention of cancer and treatment and prevention of Alzheimer’s and Parkinson’s Diseases. Importantly, the ability to administer anti-inflammatory drugs chronically at relatively high doses could enable their use as alternatives to opioids and help combat the opioid epidemic.
History
The NOSH technology platform was developed at City University of New York School of Medicine by
Dr Khosrow Kashfi
. Dr Kashfi has
published extensively
on the platform. His first publication generated
world-wide interest
in the platform and the concept of eNSAIDs.